7-Ketoabiraterone is an intermediate in synthesizing 7-Ketoabiraterone Acetate (K170980), a steroidal cytochrome P 450 17a-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.
